Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Loos

Showing results (121-130 of 215) with videos related to

Pageof 22
Sort By:
British Journal of Cancer|May 21, 2010
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignanciesP Hamberg, N Steeghs, W J Loos, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Influence of the cisplatin hydration schedule on topotecan pharmacokineticsH Gelderblom, W J Loos, A Sparreboom, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2006
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumorsA Felici, W J Loos, J Verweij, et al.
Cancer Research|April 10, 1999
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implicationsA Sparreboom, L van Zuylen, E Brouwer, et al.
Anti-Cancer Drugs|July 23, 2004
Limited cerebrospinal fluid penetration of docetaxelAlbert J ten Tije, Walter J Loos, Ming Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2010
Cisplatin-induced downregulation of OCTN2 affects carnitine wastingCynthia S Lancaster, Chaoxin Hu, Ryan M Franke, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij ratsJ H Schellens, W Van de Vrie, W J Loos, et al.
Journal of Clinical Pharmacology|May 24, 2011
Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunctionGaia Schiavon, Karel Eechoute, Ron H J Mathijssen, et al.
Anti-Cancer Drugs|August 21, 2002
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxelWalter J Loos, Janos Szebeni, Albert J ten Tije, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area valuesWalter J Loos, Felix E de Jongh, Alex Sparreboom, et al.
Pageof 22

Showing results (121-130 of 215) with videos related to

Sort By:
Pageof 22
British Journal of Cancer|May 21, 2010
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignanciesP Hamberg, N Steeghs, W J Loos, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Influence of the cisplatin hydration schedule on topotecan pharmacokineticsH Gelderblom, W J Loos, A Sparreboom, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2006
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumorsA Felici, W J Loos, J Verweij, et al.
Cancer Research|April 10, 1999
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implicationsA Sparreboom, L van Zuylen, E Brouwer, et al.
Anti-Cancer Drugs|July 23, 2004
Limited cerebrospinal fluid penetration of docetaxelAlbert J ten Tije, Walter J Loos, Ming Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2010
Cisplatin-induced downregulation of OCTN2 affects carnitine wastingCynthia S Lancaster, Chaoxin Hu, Ryan M Franke, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij ratsJ H Schellens, W Van de Vrie, W J Loos, et al.
Journal of Clinical Pharmacology|May 24, 2011
Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunctionGaia Schiavon, Karel Eechoute, Ron H J Mathijssen, et al.
Anti-Cancer Drugs|August 21, 2002
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxelWalter J Loos, Janos Szebeni, Albert J ten Tije, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area valuesWalter J Loos, Felix E de Jongh, Alex Sparreboom, et al.
Pageof 22